We are a national coalition of AIDS activists, many living with HIV/AIDS,working together to end the AIDS epidemic by advancing research on HIV/AIDS

User: Password: Remember me: Forget Password?

Enter the email address of your account below to receive your password:

Pfizer

Community Affairs Manager: Ann Prochilo

Email: aprochilo@prochilo.com

Telephone Number: 415-378-3175

Approved Drugs:

1) Rescriptor (delavirdine mesylate) – Non-Nuceloside Reverse Transcriptase Inhibitor

2) Viracept (nelfinavir mesylate) – Protease Inhibitor

3) Selzentry (U.S.), Celsentri (trade name ex-U.S.) (maraviroc) – Entry Inhibitor (Oral CCR5 antagonist)

Drugs in Pre-approval Status:

1) UK-453,061 – Non-Nuceloside Reverse Transcriptase Inhibitor (second-generation)

Comment: IAS 2007; ICAAC 2007; CROI 2008; ICAAC/IDSA 2008; Xenobiotica, Volume 38, Number 6, June 2008 , pp. 620-640 (Pre-clinical pharmacokinetics of UK-453,061...)

2) PF-232798 – Entry Inhibitor (second-generation oral CCR5 antagonist)

Comment: CROI 2008

3) PF-03716539 – Pharmacokinetic Enhancer

Comment: none to date (as of 2/27/09)

4) PF-00868554 – HCV polymerase inhibitor

Comment: AASLD 2008

5) PF-04878691 – Toll-like receptor 7 (TLR-7) agonist

Comment: none to date (as of 2/27/09)

Patient Assistance Program:

Telephone: 888-327-7787

Website: www.pfizerhelpfulanswers.com